Experimental and computational modeling of the biological activity of benzaldehyde sulphur trioxide as a potential drug for the treatment of Alzheimer disease

Abstract

Alzheimer's disease is a major public brain infection that has resulted in many deaths as revealed by the world health organization (WHO). Conventional Alzheimer treatments such as chemotherapy, surgery, and radiotherapy are not very effective and are usually associated with several adverse effects. Therefore, it is necessary to find new therapeutic approach that completely treat Alzheimer disease without much side effects. In this research work, we report the experimental and in silico molecular modeling of the biological activity of a novel azo-based compound as potential candidate for Alzheimer's disease. The synthesized compound was obtained by coupling reactions with 4-amino-3-nitrobenzaldehyde. Suitable purification and characterization techniques were employed and density functional theory (DFT) computational approach as well as in-silico molecular modeling has been employed to assess the electronic properties and anti-Alzheimer's potency. Suitable protein targets often regarded as target sites for most therapeutic vaccines for the said disease (4EY7, 1QTN, 4EY7, and 6EUE) have been selected for molecular docking investigation. For proper valuation of the drug candidacy, molecular docking studies were compared with conventional Alzheimer drug (donepezil). Also, the spectroscopic properties of the studied compound were investigated and compared with experimental data. Our findings show that the studied structure is relatively stable and expresses greater binding affinities of −6.10, −9.01, −5.90, and −11.20 kcal/mol than donepezil which had binding affinities of: 5.30, −6.30, 5.90, and −10.70 kcal/mol for each protein target. Thus, demonstrating the efficacy of the studied compound as potential candidate for Alzheimer's disease.